<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="49161"><DrugName>beclomethasone dipropionate (oral, radiation enteritis), Soligenix</DrugName><DrugNamesKey><Name id="42749771">beclomethasone dipropionate</Name><Name id="42808496">orBec</Name></DrugNamesKey><DrugSynonyms><Name><Value>beclomethasone dipropionate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>orBec</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>beclomethasone dipropionate (oral dual release), DOR BioPharma</Value></Name><Name><Value>oral BDP</Value></Name><Name><Value>beclomethasone (oral dual release), DOR BioPharma</Value></Name><Name><Value>beclometasone (oral dual release), DOR BioPharma</Value></Name><Name><Value>DOR-201</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>beclomethasone dipropionate (oral dual release), Soligenix/Sigma-Tau</Value></Name><Name><Value>SGX-201</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>beclomethasone dipropionate (oral, radiation enteritis), Soligenix</Value></Name><Name><Value>4419-39-0</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>5534-09-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="16218">Fred Hutchinson Cancer Research Center</CompanyOriginator><CompaniesPrimary><Company id="17207">Soligenix Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="16218">Fred Hutchinson Cancer Research Center</Company><Company id="19946">Leadiant Biosciences Inc</Company><Company id="29269">Corporate Technology Development Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="16218" type="Company"><TargetEntity id="5003172479" type="organizationId">Fred Hutchinson Cancer Research Center</TargetEntity></SourceEntity><SourceEntity id="17207" type="Company"><TargetEntity id="4295903924" type="organizationId">Soligenix Inc</TargetEntity></SourceEntity><SourceEntity id="19946" type="Company"><TargetEntity id="4297326430" type="organizationId">Leadiant Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="29269" type="Company"><TargetEntity id="4296104714" type="organizationId">Corporate Technology Development Inc</TargetEntity></SourceEntity><SourceEntity id="337" type="ciIndication"><TargetEntity id="K51" type="ICD10"></TargetEntity><TargetEntity id="10009900" type="MEDDRA"></TargetEntity><TargetEntity id="D003093" type="MeSH"></TargetEntity><TargetEntity id="-1993209976" type="omicsDisease"></TargetEntity><TargetEntity id="396" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="367" type="ciIndication"><TargetEntity id="10063155" type="MEDDRA"></TargetEntity><TargetEntity id="D054508" type="MeSH"></TargetEntity><TargetEntity id="-1541096986" type="omicsDisease"></TargetEntity><TargetEntity id="1818" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="578" type="ciIndication"><TargetEntity id="10064147" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="597" type="ciIndication"><TargetEntity id="10014866" type="MEDDRA"></TargetEntity><TargetEntity id="D004751" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="616" type="ciIndication"><TargetEntity id="D89.81" type="ICD10"></TargetEntity><TargetEntity id="10018651" type="MEDDRA"></TargetEntity><TargetEntity id="D006086" type="MeSH"></TargetEntity><TargetEntity id="39812" type="ORPHANET"></TargetEntity><TargetEntity id="-1437372564" type="omicsDisease"></TargetEntity><TargetEntity id="1129" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3191" type="Action"><TargetEntity id="1738" type="Mechanism">Glucocorticoid Receptor (GR) Agonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="367">Radiation sickness</Indication><Indication id="597">Enteritis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="337">Ulcerative colitis</Indication><Indication id="578">Gastrointestinal inflammation</Indication><Indication id="616">Graft versus host disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="3191">Glucocorticoid receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1465">Radioprotectant</Action><Action id="2954">Steroidal anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="595">Tablet formulation</Technology><Technology id="559">Oral controlled release formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="590">Enteric coated formulation</Technology><Technology id="764">Local formulation unspecified</Technology><Technology id="661">Oral quick release formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-05-17T10:13:01.000Z</LastModificationDate><ChangeDateLast>2019-05-30T00:00:00.000Z</ChangeDateLast><AddedDate>2004-03-12T16:56:53.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17207" linkType="Company"&gt;Soligenix&lt;/ulink&gt; (formerly &lt;ulink linkID="29269" linkType="Company"&gt;&lt;/ulink&gt;DOR BioPharma), under license from  the &lt;ulink linkID="16218" linkType="Company"&gt;Fred Hutchinson Cancer Research Center&lt;/ulink&gt;, is developing SGX-201 (DOR-201) an oral formulation of the corticosteroid beclomethasone 17, 21-dipropionate dosed as one immediate-release tablet and one enteric-coated tablet, for the potential prevention of radiation sickness including  acute radiation enteritis [&lt;ulink linkID="841004" linkType="Reference"&gt;841004&lt;/ulink&gt;], [&lt;ulink linkID="1045931" linkType="Reference"&gt;1045931&lt;/ulink&gt;], [&lt;ulink linkID="1065269" linkType="Reference"&gt;1065269&lt;/ulink&gt;], [&lt;ulink linkID="1161931" linkType="Reference"&gt;1161931&lt;/ulink&gt;], [&lt;ulink linkID="1161991" linkType="Reference"&gt;1161991&lt;/ulink&gt;], [&lt;ulink linkID="1173579" linkType="Reference"&gt;1173579&lt;/ulink&gt;], [&lt;ulink linkID="1290281" linkType="Reference"&gt;1290281&lt;/ulink&gt;], [&lt;ulink linkID="1352939" linkType="Reference"&gt;1352939&lt;/ulink&gt;]. In December 2009, a phase I/II trial for the prevention of acute radiation enteritis began [&lt;ulink linkID="1065269" linkType="Reference"&gt;1065269&lt;/ulink&gt;]; in February 2012, positive preliminary results were reported [&lt;ulink linkID="1261793" linkType="Reference"&gt;1261793&lt;/ulink&gt;]. In March 2016, a phase II trial of SGX-201 for radiation enteritis was expected to begin in 2H17 [&lt;ulink linkID="1747120" linkType="Reference"&gt;1747120&lt;/ulink&gt;]. In March 2018, Soligenix noted that SGX-201 was contingent upon continued government contract/grant funding or other funding source [&lt;ulink linkID="2017254" linkType="Reference"&gt;2017254&lt;/ulink&gt;]. In July 2018, the study  design in this indication was still under development [&lt;ulink linkID="2051331" linkType="Reference"&gt;2051331&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company is also developing the drug as &lt;ulink linkID="116385" linkType="Drug"&gt;SGX-203&lt;/ulink&gt; for    the potential treatment of pediatric  Crohn's disease and as &lt;ulink linkID="116384" linkType="Drug"&gt;OrbeShield&lt;/ulink&gt; for    the potential treatment of radiation injury including gastrointestinal acute radiation syndrome.&lt;/para&gt;&lt;para&gt;In March 2015, Soligenix was considering developing the drug for local inflammation associated with ulcerative colitis, among other indications [&lt;ulink linkID="1646210" linkType="Reference"&gt;1646210&lt;/ulink&gt;]. However, no further development was reported since that time.&lt;/para&gt;&lt;para&gt;Soligenix was previously developing the drug as orBec for the potential treatment and prevention of graft-versus-host disease (GvHD). In November 2006, the EMEA validated an MAA application for gastrointestinal GvHD [&lt;ulink linkID="746971" linkType="Reference"&gt;746971&lt;/ulink&gt;]; however, in May 2008, DOR voluntarily withdrew the application following discussions with the EMEA regarding the need for confirmation of clinical efficacy. At that time, a named patient program was to be initiated in Europe alongside a confirmatory phase III trial [&lt;ulink linkID="908901" linkType="Reference"&gt;908901&lt;/ulink&gt;]; by September 2008, the product was available under named patient protocols in Europe for GvHD [&lt;ulink linkID="944104" linkType="Reference"&gt;944104&lt;/ulink&gt;]. In October 2007, the FDA issued a not-approvable letter  in response to an NDA  for intestinal GvHD [&lt;ulink linkID="841004" linkType="Reference"&gt;841004&lt;/ulink&gt;]. In November 2008, the FDA agreed to the phase III study design for acute gastrointestinal GvHD [&lt;ulink linkID="961553" linkType="Reference"&gt;961553&lt;/ulink&gt;]; in January 2009, the FDA agreed the trial was to be conducted under an SPA [&lt;ulink linkID="973973" linkType="Reference"&gt;973973&lt;/ulink&gt;]; in October 2009, the trial began [&lt;ulink linkID="1049742" linkType="Reference"&gt;1049742&lt;/ulink&gt;]; however, in  September 2011, the company reported that  the trial would be stopped based on the pre-specified interim analysis as it was unlikely to attain the primary efficacy objective [&lt;ulink linkID="1222840" linkType="Reference"&gt;1222840&lt;/ulink&gt;]; by February 2013, the trial had been discontinued [&lt;ulink linkID="1386356" linkType="Reference"&gt;1386356&lt;/ulink&gt;] and at that time, the drug was listed as being in phase I development on Soligenix's pipeline [&lt;ulink linkID="1386624" linkType="Reference"&gt;1386624&lt;/ulink&gt;].  In December 2013, a phase II trial was initiated in patients with  chronic gastrointestinal GvHD  [&lt;ulink linkID="1505323" linkType="Reference"&gt;1505323&lt;/ulink&gt;], [&lt;ulink linkID="1505019" linkType="Reference"&gt;1505019&lt;/ulink&gt;]; however, in March 2015, the program was no longer listed on the pipeline for GvHD [&lt;ulink linkID="1639231" linkType="Reference"&gt;1639231&lt;/ulink&gt;], [&lt;ulink linkID="1639237" linkType="Reference"&gt;1639237&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Licensee &lt;ulink linkID="19946" linkType="Company"&gt;Sigma-Tau Pharmaceuticals&lt;/ulink&gt; was collaborating with Soligenix on the development of orBec for GvHD [&lt;ulink linkID="983579" linkType="Reference"&gt;983579&lt;/ulink&gt;], [&lt;ulink linkID="1210838" linkType="Reference"&gt;1210838&lt;/ulink&gt;]. However, in August 2012, Sigma no longer listed the drug on its pipeline [&lt;ulink linkID="1315508" linkType="Reference"&gt;1315508&lt;/ulink&gt;], and in December 2012, Soligenix confirmed it had regained the North American and European rights to the drug [&lt;ulink linkID="1352939" linkType="Reference"&gt;1352939&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In November 2007, the Australian Patent Office granted the issuance of patent  2002254205, entitled 'Method of treating inflammatory conditions of the gastrointestinal tract using topically active corticosteroids' that covers the use of oral beclomethasone in GvHD [&lt;ulink linkID="855378" linkType="Reference"&gt;855378&lt;/ulink&gt;]. In March 2015, Soligenix stated that &lt;ulink linkID="PA3087032" linkType="Patent"&gt;US-08263582&lt;/ulink&gt; (expiring in March 2022) and &lt;ulink linkID="IN2732180" linkType="Patent"&gt;US-06096731&lt;/ulink&gt; (expiring in June 2018) cover the use of the drug for inflammatory disorders of the gastrointestinal tract and the prevention and treatment of GI GVHD, respectively.  &lt;ulink linkID="PA3314473" linkType="Patent"&gt;EP-01392321&lt;/ulink&gt; (expiring in March 2022) covers the use of topically active corticosteroids in orally administered  forms for  inflammation in the upper and lower gastrointestinal tract, and &lt;ulink linkID="PA6234395" linkType="Patent"&gt;EP-02242477&lt;/ulink&gt; (expiring in January 2029) covers the use of oral  beclomethasone 17, 21-dipropionate for interstitial lung disease. US patent application 12/633,631 (filed in December 2009) and corresponding European patent application 09836727.9 cover the use of topically active beclomethasone 17, 21-dipropionate for radiation and chemotherapeutics injury. By March 2015, the drug was also covered by several issued or pending patent in countries including Australia, Canada, China, Hong Kong, Israel, India, Japan, South Korea and New Zealand [&lt;ulink linkID="1646210" linkType="Reference"&gt;1646210&lt;/ulink&gt;]. In March 2018, this was still the case [&lt;ulink linkID="2017254" linkType="Reference"&gt;2017254&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Radiation enteritis&lt;/subtitle&gt;In January 2009, SGX-201 received US Fast Track status  for the prevention of acute radiation enteritis [&lt;ulink linkID="974236" linkType="Reference"&gt;974236&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Graft-versus-host disease&lt;/subtitle&gt;In September 2001, the FDA granted Orphan Drug designation for the use of orBec to prevent GvHD [&lt;ulink linkID="526354" linkType="reference"&gt;526354&lt;/ulink&gt;]. By October 2001, the FDA had also granted orBec Fast Track status for treatment of intestinal GvHD [&lt;ulink linkID="424967" linkType="reference"&gt;424967&lt;/ulink&gt;]. In August 2009, the FDA granted orBec Orphan Drug status for  chronic gastrointestinal GvHD in patients who had undergone allogeneic hematopoietic cell transplantation [&lt;ulink linkID="1030883" linkType="Reference"&gt;1030883&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, the company anticipated that it would file an NDA by the end of 2004 [&lt;ulink linkID="548214" linkType="Reference"&gt;548214&lt;/ulink&gt;]. In November 2004, an NDA filing was expected in April 2005 [&lt;ulink linkID="570546" linkType="Reference"&gt;570546&lt;/ulink&gt;]. In February 2005, a meeting to discuss a possible NDA was planned with the FDA [&lt;ulink linkID="583221" linkType="Reference"&gt;583221&lt;/ulink&gt;]. In April 2005, based on a meeting with the  FDA, the company intended to file an NDA for GvHD by the fourth quarter of 2005 [&lt;ulink linkID="596513" linkType="Reference"&gt;596513&lt;/ulink&gt;].  In October 2005, the IND for orBec was transferred from the FDA's Gastrointestinal Products Division to the Oncology Drug Products Division. By that time, DOR had submitted a response to the Oncology Division's  questions regarding orBec in transplantation [&lt;ulink linkID="628667" linkType="Reference"&gt;628667&lt;/ulink&gt;].  In November 2005, following a meeting with the FDA, the company said it planned to file an NDA for orBec in early 2006 [&lt;ulink linkID="634807" linkType="Reference"&gt;634807&lt;/ulink&gt;]. In September 2006, an NDA was filed  [&lt;ulink linkID="692969" linkType="Reference"&gt;692969&lt;/ulink&gt;]; in November 2006, the FDA accepted it for standard review, with a target action date of July 2007 for completion of the review [&lt;ulink linkID="744541" linkType="Reference"&gt;744541&lt;/ulink&gt;]; in January 2007, the agency set a PDUFA date of July 21, 2007  [&lt;ulink linkID="762416" linkType="Reference"&gt;762416&lt;/ulink&gt;]; and in May 2007, DOR released briefing documents for the FDA's ODAC meeting which was to take place on  May 09, 2007 [&lt;ulink linkID="791754" linkType="Reference"&gt;791754&lt;/ulink&gt;], [&lt;ulink linkID="791817" linkType="Reference"&gt;791817&lt;/ulink&gt;]. Later that month,  the FDA's ODAC  voted 7 to 2 that  data in the NDA did not show substantial efficacy  for GvHD [&lt;ulink linkID="792629" linkType="Reference"&gt;792629&lt;/ulink&gt;], [&lt;ulink linkID="822152" linkType="Reference"&gt;822152&lt;/ulink&gt;].  In July 2007, the FDA extended orBec's PDUFA marketing approval date to the end of October, 2007 as it was reviewing the drug's supplementary data   [&lt;ulink linkID="814571" linkType="Reference"&gt;814571&lt;/ulink&gt;] and by July 2007, the FDA had set the date as October 21, 2007 [&lt;ulink linkID="817151" linkType="Reference"&gt;817151&lt;/ulink&gt;], [&lt;ulink linkID="822152" linkType="Reference"&gt;822152&lt;/ulink&gt;]. In October 2007, the agency issued a not-approvable letter  requesting data from additional safety and efficacy clinical studies and further information on other sections of the NDA. DOR planned to meet with the FDA before deciding on its next steps for the drug [&lt;ulink linkID="841004" linkType="Reference"&gt;841004&lt;/ulink&gt;]. In December 2007, following discussion with the FDA, the company planned a phase III trial and a SPA meeting with the FDA 'in the near future'. The agency was to review a plan for a treatment IND providing that it did not interfere with patient accrual in the planned trial [&lt;ulink linkID="858745" linkType="Reference"&gt;858745&lt;/ulink&gt;]; in November 2008, the FDA agreed to   DOR's phase III  study design for acute gastrointestinal GvHD. The trial was expected to begin in the first half of 2009 [&lt;ulink linkID="961553" linkType="Reference"&gt;961553&lt;/ulink&gt;]. In January 2009, the FDA agreed the trial was to be conducted under an SPA [&lt;ulink linkID="973973" linkType="Reference"&gt;973973&lt;/ulink&gt;]. In September 2011, the company reported that  the trial would be stopped based on the pre-specified interim analysis of the DSMB as it was unlikely to attain the primary efficacy objective. At that time, the company expected to analyze the data in the 'upcoming weeks' [&lt;ulink linkID="1222840" linkType="Reference"&gt;1222840&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In February 2002, the EMEA granted Orphan drug status for orBec for intestinal GvHD [&lt;ulink linkID="527176" linkType="reference"&gt;527176&lt;/ulink&gt;]. In April 2005, the company expected to begin preparing to file an MAA with the EMEA for intestinal GvHD [&lt;ulink linkID="596513" linkType="Reference"&gt;596513&lt;/ulink&gt;]. In November 2005, following a meeting with European regulatory authorities, it planned to submit an MAA in the first half of 2006 [&lt;ulink linkID="634807" linkType="Reference"&gt;634807&lt;/ulink&gt;]. In November 2006, the MAA for gastrointestinal GvHD was submitted [&lt;ulink linkID="740161" linkType="Reference"&gt;740161&lt;/ulink&gt;]; the EMEA validated the application [&lt;ulink linkID="746971" linkType="Reference"&gt;746971&lt;/ulink&gt;]. In May 2008, DOR voluntarily withdrew the MAA following discussions with the EMEA regarding the requirement for confirmatory phase III data [&lt;ulink linkID="908901" linkType="Reference"&gt;908901&lt;/ulink&gt;]. In June 2009, the company received protocol assistance feedback from the EMEA which confirmed positive data from the new phase III trial would be sufficient for European marketing approval [&lt;ulink linkID="1016588" linkType="Reference"&gt;1016588&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt; In November 2007,  DOR BioPharma  intended to initiate a named patient access program  for the drug in  South Africa  [&lt;ulink linkID="855378" linkType="Reference"&gt;855378&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In November 2007,  DOR BioPharma  intended to initiate a named patient access program  for the drug in New Zealand   [&lt;ulink linkID="855378" linkType="Reference"&gt;855378&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2008,   a named patient  program was being planned for South Korea  [&lt;ulink linkID="877244" linkType="Reference"&gt;877244&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In mid-2008, named patient access programs were planned for other territories in Asia  [&lt;ulink linkID="926265" linkType="Reference"&gt;926265&lt;/ulink&gt;],  [&lt;ulink linkID="938480" linkType="Reference"&gt;938480&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2008, the Australian Therapeutics Goods Administrations granted the drug Orphan Drug status for gastrointestinal GvHD following allogeneic hematopoietic cell transplantation  [&lt;ulink linkID="966422" linkType="Reference"&gt;966422&lt;/ulink&gt;]. By November 2008, the company had begun a named patient access program for gastrointestinal GvHD in Australia [&lt;ulink linkID="966422" linkType="Reference"&gt;966422&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Radiation enteritis&lt;/subtitle&gt;In March 2016, a phase II trial of SGX-201 for radiation enteritis was expected to begin in the second half of 2017 [&lt;ulink linkID="1747120" linkType="Reference"&gt;1747120&lt;/ulink&gt;]. In July 2018, the study  design in this indication was still under development [&lt;ulink linkID="2051331" linkType="Reference"&gt;2051331&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, the FDA approved a phase I/II trial of SGX-201 for the prevention of acute radiation enteritis. The four-arm, multicenter, open-label, sequential, dose-escalation, BDP-ENT-01 study would evaluated the drug's safety, maximum tolerated dose and preliminary efficacy in 36 rectal cancer patients, scheduled to undergo concurrent radiation and chemotherapy prior to surgery [&lt;ulink linkID="969221" linkType="Reference"&gt;969221&lt;/ulink&gt;]. In December 2009, a phase I/II trial for the prevention of acute radiation enteritis began. The multicenter, open-label, sequential, dose-escalation study (&lt;ulink linkID="64387" linkType="Protocol"&gt;NCT01073384&lt;/ulink&gt;; 1R43CA141968-01; BDP-ENT-01) would enroll 36 patients with rectal cancer scheduled to undergo radio- and chemotherapy before surgery and assess the safety and maximum tolerated dose of SGX-201, as well its preliminary efficacy [&lt;ulink linkID="1065269" linkType="Reference"&gt;1065269&lt;/ulink&gt;]. In March 2011, patient enrollment  (expected n = 48) was ongoing [&lt;ulink linkID="1175709" linkType="Reference"&gt;1175709&lt;/ulink&gt;]. In February 2012, preliminary results from 16 patients showed the drug was safe and well tolerated and there was evidence of a potential dose response with respect to diarrhea, nausea and vomiting and assessment of enteritis [&lt;ulink linkID="1261793" linkType="Reference"&gt;1261793&lt;/ulink&gt;]. In November 2012, the trial was completed [&lt;ulink linkID="1175709" linkType="Reference"&gt;1175709&lt;/ulink&gt;], [&lt;ulink linkID="2017254" linkType="Reference"&gt;2017254&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Graft-versus-host disease&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2009, data from two randomized, double-blind, placebo-controlled, phase II and phase III trials of orBec for acute GI GvHD were published by the &lt;ulink linkID="16218" linkType="Company"&gt;Fred Hutchinson Cancer Research Center&lt;/ulink&gt;. Data from 120 patients were included in the retrospective analysis and OrBec was shown to decrease non-infectious inflammation of the lung in acute GI GvHD patients who received allogeneic hematopoietic cell transplants [&lt;ulink linkID="1022148" linkType="Reference"&gt;1022148&lt;/ulink&gt;], [&lt;ulink linkID="1021878" linkType="Reference"&gt;1021878&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007, following a discussion with the FDA over the not-approvable letter, DOR planned a phase III confirmatory trial for intestinal GvHD [&lt;ulink linkID="858745" linkType="Reference"&gt;858745&lt;/ulink&gt;]. In November 2008, the FDA agreed to   DOR's phase III  study design for acute gastrointestinal GvHD. The trial was expected to begin in the first half of 2009 after final FDA clearance [&lt;ulink linkID="961553" linkType="Reference"&gt;961553&lt;/ulink&gt;]. In January 2009, the company reached an agreement with the FDA to conduct the trial under a SPA. The double-blind, randomized, placebo-controlled, multicenter trial was expected to enroll 166 patients. The primary endpoint was treatment failure rate at day 80 [&lt;ulink linkID="973973" linkType="Reference"&gt;973973&lt;/ulink&gt;]. In March 2009, the trial was expected to begin in the second half of 2009 [&lt;ulink linkID="994627" linkType="Reference"&gt;994627&lt;/ulink&gt;]. In October 2009, the SUPPORTS trial began. At that time, data were expected in the first half of 2011 [&lt;ulink linkID="1049742" linkType="Reference"&gt;1049742&lt;/ulink&gt;]. In September 2010, completion was expected in the second half of 2011 [&lt;ulink linkID="1134372" linkType="Reference"&gt;1134372&lt;/ulink&gt;]. In July 2011, it was reported that the trial was being conducted throughout the US, Europe, and Australia [&lt;ulink linkID="1210838" linkType="Reference"&gt;1210838&lt;/ulink&gt;]. In September 2011, the company reported that  the trial would be stopped based on the pre-specified interim analysis of the DSMB as it was unlikely to attain the primary efficacy objective. At that time, 140 patients had been enrolled and the company expected to analyze the data in the 'upcoming weeks' [&lt;ulink linkID="1222840" linkType="Reference"&gt;1222840&lt;/ulink&gt;]. By February 2013, the trial had been discontinued [&lt;ulink linkID="1386356" linkType="Reference"&gt;1386356&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January  2006, DOR reported results from an FDA-requested comparative analysis of survival data from the phase II  and phase III trials. The 200-day post transplant mortality rate in the phase II trial was found to be consistent with the 70% reduction in mortality seen in the phase III trial . The analysis also revealed that there had been no imbalance in the phase III group between the treatment and placebo groups that could have favored orBec; there was in fact a larger proportion of higher-risk patients in the treatment group [&lt;ulink linkID="646182" linkType="Reference"&gt;646182&lt;/ulink&gt;]. In February 2006, similar data were reported by the company, following a presentation at the annual Tandem Bone Marrow Transplant Meeting of the American Society for Blood and Marrow Transplantation and the International Bone marrow Transplant Registry in Honolulu, HI [&lt;ulink linkID="651395" linkType="Reference"&gt;651395&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2003, DOR revealed that preliminary data from its phase III, multicenter, double-blind, placebo-controlled trial of orBec in GvHD had shown that the drug appeared to be well tolerated. At that time, the company hoped to complete enrollment by the end of the first quarter of 2004 and to file a NDA in the fourth quarter of 2004 [&lt;ulink linkID="507279" linkType="reference"&gt;507279&lt;/ulink&gt;]; the 129-patient  trial was completed in September 2004 [&lt;ulink linkID="559307" linkType="Reference"&gt;559307&lt;/ulink&gt;]. In December 2004, top-line results from this trial were announced. The drug failed to show benefit for its primary endpoint of time to treatment failure up to day 50. It did, however, show benefit for the secondary endpoint of time to treatment failure up to day 80, and significantly reduced mortality. All patients were initially treated with 1 to 2 mg/kg/day prednisone in combination with orBec (8 mg/day) or placebo for the first 10 days. On day 10, if patients were responding, the prednisone dosing was tapered and patients continued to receive either orBec or placebo for 40 days. Treatment failure rate at day 50 was 31% for the orBec group and 48% for the placebo group. At day 80, failure rate was 39% in the orBec group and 65% in the placebo group, Mortality at 200 days post-transplant was 8% for patients receiving orBec and 26% for placebo patients. DOR believed that the lack of benefit shown at day 50 was due to a higher than expected rate of treatment failures during days 0 to 10 of the study. The company intended to further analyze the day 0 to 10 treatment failure group and the impact of this group on the primary endpoint [&lt;ulink linkID="577846" linkType="Reference"&gt;577846&lt;/ulink&gt;]. In January 2005, the company was intending to meet with the FDA to discuss the results as soon as possible [&lt;ulink linkID="578861" linkType="Reference"&gt;578861&lt;/ulink&gt;]. In January 2007, similar data were reported. At 1 year after randomization, orBec showed continued survival benefit when compared with  placebo. A total of 18 patients (29%) in the orBec treatment group and 28 patients (42%) in the placebo group died within 1 year of the start of the trial, representing a 46% reduction in mortality. OrBec treatment cut the risk of mortality during the 200-day post-transplant period by 67% , however statistical significance for the primary endpoint, which was time to treatment failure through day 50, was not achieved. However, orBec did achieve statistical significance in other endpoints including lowering the risk of treatment failure up to day 80 and long-term survival advantage. The most common  causes of death by 200 days  were relapse of the underlying malignancy and infection,   which contributed to the deaths of 13.4% of placebo patients and  4.8% of patients in the orBec arm. A total of 4.5% of patients in the placebo arm and 1.6% of orBec-treated patients died from acute or chronic GvHD. The frequencies of severe adverse events, adverse events related to orBec, and adverse events resulting in  discontinuation of orBec treatment were all comparable with placebo for both phase II and III studies. However, patients who continued orBec treatment until day 50 in the pivotal study had a higher likelihood of having biochemical evidence of abnormal HPA function compared with the placebo patients [&lt;ulink linkID="759657" linkType="Reference"&gt;759657&lt;/ulink&gt;], [&lt;ulink linkID="759915" linkType="Reference"&gt;759915&lt;/ulink&gt;]. Similar data were published in October 2007 [&lt;ulink linkID="837785" linkType="Reference"&gt;837785&lt;/ulink&gt;], [&lt;ulink linkID="837590" linkType="Reference"&gt;837590&lt;/ulink&gt;]. In April 2012, the trial was terminated due to futility  [&lt;ulink linkID="1292568" linkType="Reference"&gt;1292568&lt;/ulink&gt;], [&lt;ulink linkID="1292569" linkType="Reference"&gt;1292569&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2001, orBec was in a multicenter pivotal phase III trial for intestinal GVHD [&lt;ulink linkID="424967" linkType="reference"&gt;424967&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In November 2013, the company expected to initiate a phase II trial in chronic gastrointestinal GvHD in the fourth quarter of 2013 [&lt;ulink linkID="1498841" linkType="Reference"&gt;1498841&lt;/ulink&gt;]. In December 2013, a randomized, double-blind, placebo-controlled, multicenter, safety and efficacy phase II study (&lt;ulink linkID="151308" linkType="Protocol"&gt;NCT01925950&lt;/ulink&gt;; BDP-GVHD-08) of the drug was initiated in patients (estimated n = 40) with chronic  gastrointestinal GvHD. The study was expected to complete in April 2016 [&lt;ulink linkID="1505323" linkType="Reference"&gt;1505323&lt;/ulink&gt;], [&lt;ulink linkID="1505019" linkType="Reference"&gt;1505019&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2012, a multicentre, open-label, pilot phase II trial  in patients who received allogeneic hematopoietic cell transplantation at least 100 days earlier; have had chronic GVHD in at least one organ outside the GI tract, and have a GI biopsy consistent with chronic GI GVHD, receiving orBec x16 weeks, is planned in the first half of 2013. The primary efficacy objectives would be complete, partial  and overall response [&lt;ulink linkID="1320095" linkType="Reference"&gt;1320095&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2008, data from a randomized, single-center, 120-patient clinical study were reported at the annual tandem Bone Marrow Transplant Meeting of the American Society for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry in San Diego, CA. Patients with acute  GVHD received orBec or placebo. Significantly fewer orBec-treated patients had deterioration of pulmonary diffusing capacity by transplant day 80,  than placebo-treated patients. There were no non-infectious pulmonary problems were seen in the orBec group compared with 4 patients in the placebo group during a 200-day observation period. At that time, the company  was considering development   of the drug for   pulmonary inflammatory disorders  [&lt;ulink linkID="876325" linkType="Reference"&gt;876325&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, FDA approval was received to begin a phase II trial  for acute GvHD. In the randomized, double-blind, placebo-controlled trial, 138 patients would receive orBec or placebo for 75 days after hematopoietic cell transplantation to evaluate its effect on the incidence and severity of acute GvHD. At that time, enrollment was to start in the second quarter of 2007 [&lt;ulink linkID="777950" linkType="Reference"&gt;777950&lt;/ulink&gt;]. Enrollment in the trial began in July 2007. Subjects would receive  orBec or placebo for 75 days after hematopoietic cell transplantation. The primary endpoint was the proportion of subjects who developed acute GvHD sufficient to require systemic immunosuppressive treatment on or before day 90 after transplantation [&lt;ulink linkID="812656" linkType="Reference"&gt;812656&lt;/ulink&gt;], [&lt;ulink linkID="822152" linkType="Reference"&gt;822152&lt;/ulink&gt;]. In April 2010, enrollment was ongoing [&lt;ulink linkID="1086881" linkType="Reference"&gt;1086881&lt;/ulink&gt;]. In May 2010, enrollment (n = 140) was completed and  results were expected in the second half of 2010 [&lt;ulink linkID="1098718" linkType="Reference"&gt;1098718&lt;/ulink&gt;]. In October 2010, data from the trial were presented showing the primary endpoint was not met. There were fewer cases of acute GvHD grades IIb to IV compared with placebo (21 versus 33%) but the difference was not significant. The drug was safe and well tolerated. At that time, data analysis was ongoing [&lt;ulink linkID="1141790" linkType="Reference"&gt;1141790&lt;/ulink&gt;].  In November 2011, data from the proof-of-concept phase II study published had shown that orBec or placebo (1 mg immediate-release formulation plus 1 mg delayed-release formulation) did not achieve statistical significance in the primary endpoint. There was no statistically significant differences between the two arms in the secondary endpoint. The proportion of patients who took at least 90% of orBec during the first 4 weeks after HCT was 54% overall. Lower severity of mucositis strongly correlated with higher adherence to the schedule of orBec. The drug was safe and well tolerated  [&lt;ulink linkID="1247897" linkType="Reference"&gt;1247897&lt;/ulink&gt;], [&lt;ulink linkID="1247603" linkType="Reference"&gt;1247603&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 1998, results were published from a randomized, double-blind, phase II  trial of the drug, conducted by the &lt;ulink linkID="16218" linkType="Company"&gt;Fred Hutchinson Cancer Research Center&lt;/ulink&gt;, in 60 patients with iGvHD. Subjects received an induction course of conventional prednisone therapy plus either orBec or placebo. Responders continued to take orBec or placebo for 20 days, during which time the prednisone therapy was rapidly tapered. The primary endpoint for this study was the whether iGvHD patients at day 30 were able to consume at least 70% of their daily caloric intake by mouth. The treatment response at study day 30 was 22 of 31 (71%) for the orBec group compared to 12 of 29 (41%) on placebo [&lt;ulink linkID="646336" linkType="Reference"&gt;646336&lt;/ulink&gt;], [&lt;ulink linkID="646182" linkType="Reference"&gt;646182&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By October 2007, animal studies were ongoing for radiation injury, supported by the NIH [&lt;ulink linkID="841004" linkType="Reference"&gt;841004&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, DOR reported that orBec had demonstrated positive results in preliminary experiments with animal models of IBS-like pain. At this time, DOR was planning to conduct a phase II trial in patients who suffered from post-infection IBS [&lt;ulink linkID="526373" linkType="reference"&gt;526373&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;The drug consists of two tablets; one  releasing beclomethasone in the proximal portions of gastrointestinal tract and the second   releasing beclomethasone in the distal portions  [&lt;ulink linkID="1222840" linkType="Reference"&gt;1222840&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2008, DOR formed a European Medical Advisory Board (MAB) to provide medical and clinical guidance to the company during the development of orBec [&lt;ulink linkID="944104" linkType="Reference"&gt;944104&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="367">Radiation sickness</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-21T00:00:00.000Z</StatusDate><Source id="1065269" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="597">Enteritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-21T00:00:00.000Z</StatusDate><Source id="1065269" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19946">Leadiant Biosciences Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-08-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17207">Soligenix Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-08-26T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-02-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="578">Gastrointestinal inflammation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19946">Leadiant Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-08-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17207">Soligenix Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-07-28T00:00:00.000Z</StatusDate><Source id="1210838" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16218">Fred Hutchinson Cancer Research Center</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-11-24T00:00:00.000Z</StatusDate><Source id="1646210" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19946">Leadiant Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-12T00:00:00.000Z</StatusDate><Source id="983579" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19946">Leadiant Biosciences Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-07-28T00:00:00.000Z</StatusDate><Source id="1210838" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17207">Soligenix Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-07-28T00:00:00.000Z</StatusDate><Source id="1210838" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-27T00:00:00.000Z</StatusDate><Source id="1386624" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-12-02T00:00:00.000Z</StatusDate><Source id="1505019" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16218">Fred Hutchinson Cancer Research Center</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-07-31T00:00:00.000Z</StatusDate><Source id="646336" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-11-24T00:00:00.000Z</StatusDate><Source id="1646210" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="578">Gastrointestinal inflammation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-25T00:00:00.000Z</StatusDate><Source id="1646210" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-25T00:00:00.000Z</StatusDate><Source id="1646210" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29269">Corporate Technology Development Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-09T00:00:00.000Z</StatusDate><Source id="424967" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17207">Soligenix Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-11-07T00:00:00.000Z</StatusDate><Source id="740161" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-09-22T00:00:00.000Z</StatusDate><Source id="692969" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="367">Radiation sickness</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-10-19T00:00:00.000Z</StatusDate><Source id="829737" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17207">Soligenix Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-09T00:00:00.000Z</StatusDate><Source id="424967" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17207">Soligenix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-09T00:00:00.000Z</StatusDate><Source id="424967" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="17207">Soligenix Inc</OwnerCompany><Country id="US">US</Country><Indication id="597">Enteritis</Indication><AwardedIndication>Prevention of acute radiation enteritis</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-01-06T00:00:00.000Z</MileStoneDate><Source id="974236" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17207">Soligenix Inc</OwnerCompany><Country id="US">US</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>Treatment of gastrointestinal symptoms with chronic graft versed host disease in patients undergoing allogenic hematopoietic cell transplantation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-07-24T00:00:00.000Z</MileStoneDate><Source id="1030883" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17207">Soligenix Inc</OwnerCompany><Country id="AU">Australia</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>For the treatment of patients with gastrointestinal Graft-Versus-Host-Disease (GVHD) following allogenic haematopoietic cell transplantation in conjunction with an induction course of high-dose prednisone or methylprednisolone.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-10-31T00:00:00.000Z</MileStoneDate><Source id="966422" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17207">Soligenix Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>Treatment of intestinal graft-versus-host disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-03-13T00:00:00.000Z</MileStoneDate><Source id="527176" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17207">Soligenix Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>Treatment of intestinal graft-versus-host disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-01-23T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17207">Soligenix Inc</OwnerCompany><Country id="US">US</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>Prevention of gastrointestinal graft-versus-host disease</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-08-28T00:00:00.000Z</MileStoneDate><Source id="526354" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17207">Soligenix Inc</OwnerCompany><Country id="US">US</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>For oral administration in the treatment of intestinal graft-versus-host disease.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-03-27T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00822"><Name>Glucocorticoid receptor</Name><SwissprotNumbers><Swissprot>O13186</Swissprot><Swissprot>O46567</Swissprot><Swissprot>O73673</Swissprot><Swissprot>P04150</Swissprot><Swissprot>P06536</Swissprot><Swissprot>P06537</Swissprot><Swissprot>P35547</Swissprot><Swissprot>P49115</Swissprot><Swissprot>P49843</Swissprot><Swissprot>P49844</Swissprot><Swissprot>P59667</Swissprot><Swissprot>P79269</Swissprot><Swissprot>P79686</Swissprot><Swissprot>Q5R9P5</Swissprot><Swissprot>Q95267</Swissprot><Swissprot>Q9N1U3</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2151335" linkType="reference" linkID="2151335"&gt;2151335&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1031376">Numoda Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1037227">BL&amp;H Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1040171">Tanner Pharma Group Plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1040911">Steward Cross Pte Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1041843">Pacific Healthcare Thailand Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1062207">Clinigen Group plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1141701">Leadiant Biosciences Spa</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16218">Fred Hutchinson Cancer Research Center</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17207">Soligenix Inc</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>14</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>4</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>4</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="21864">University of Texas System</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29366">Sigma Pharmaceuticals Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C</Smiles><Smiles>CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)Cl)O)C)C)OC(=O)CC</Smiles></StructureSmiles><Deals><Deal id="110915" title="Orphan Australia to sponsor DOR's orBec NPAP in Australia, New Zealand and South Africa for GvHD"></Deal><Deal id="111650" title="BL&amp;H to sponsor DOR's orBec NPP for GvHD in South Korea"></Deal><Deal id="113593" title="DOR BioPharma to use Numoda's services for a phase III trial of orBec"></Deal><Deal id="113952" title="IDIS to supply DOR BioPharma's orBec in the EU"></Deal><Deal id="114082" title="Steward Cross to sponsor DOR's orBec NPAP in Singapore and Malaysia"></Deal><Deal id="115213" title="Pacific to sponsor DOR's orBec NPAP in various ASEAN countries"></Deal><Deal id="115788" title="BurnsAdler Pharmaceuticals to distribute DOR's orBEC NPAP in Central America, South America and the Caribbean"></Deal><Deal id="118340" title="Sigma-Tau to license DOR BioPharma's orBec for GI GVHD in North America and Europe"></Deal><Deal id="123277" title="FDA to provide funding to DOR BioPharma's orBec development for intestinal graft-versus-host disease              "></Deal><Deal id="123278" title="University of Texas Medical Branch at Galveston to acquire DOR BioPharma's patents relating to oral luminally active anti-inflammatory drugs "></Deal><Deal id="127869" title="NIH to award DOR BioPharma SBIR grant for trials of DOR-201 for radiation enteritis"></Deal><Deal id="132928" title="US government to fund Soligenix' orBec development for GI GVHD"></Deal><Deal id="133742" title="NCI to award Soligenix funding to support SGX-201 clinical trials for acute enteritis and GI manifestation of GVHD      "></Deal><Deal id="140496" title="FHCRC to collaborate with Soligenix to conduct preclinical studies of OrbeShield to treat GI ARS"></Deal></Deals><PatentFamilies><PatentFamily id="140802" number="WO-2010077681" title="Topically active steroids for use in radiation and chemotherapeutics injury"></PatentFamily><PatentFamily id="1805754" number="WO-02074316" title="Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids"></PatentFamily><PatentFamily id="2541973" number="WO-2013082541" title="Method of preventing acute graft-versus-host disease using oral beclomethasone dipropionate"></PatentFamily><PatentFamily id="2755742" number="MY-00148085" title="Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone"></PatentFamily><PatentFamily id="3170984" number="WO-2009094641" title="Topically active steroids for use in interstitial pulmonary fibrosis"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tanner Pharma Group Plc" id="1040171"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Steward Cross Pte Ltd" id="1040911"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pacific Healthcare Thailand Co Ltd" id="1041843"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Leadiant Biosciences Spa" id="1141701"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Soligenix Inc" id="17207"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Immunova Ltd" id="24633"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>